U.S. Markets closed

Albany Molecular Research, Inc. (AYM.F)

Frankfurt Stock Exchange - Frankfurt Stock Exchange Delayed Price. Currency in EUR
Add to watchlist
18.113-0.149 (-0.816%)
At close: 12:14PM CEST
Full screen
Previous Close18.262
Bid18.294 x 26300
Ask18.659 x 25300
Day's Range18.060 - 18.113
52 Week Range11.857 - 19.473
Avg. Volume6
Market Cap783.08M
PE Ratio (TTM)-10.29
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • American City Business Journals4 days ago

    AMRI shareholders approve sale of company

    Shareholders of Albany Molecular Research Inc. on Friday approved the sale of the pharmaceutical research company to affiliates of private-equity firms based in Chicago and Washington, D.C. The vote comes a little more than two months after the drug developer's board unanimously approved the sale of the AMRI to affiliates of The Carlyle Group and GTCR LLC . The private-equity firms have agreed to pay $21.75 per share, an equivalent of more than $900 million to purchase the Albany, New York, region's third-largest public company.

  • Reuters3 months ago

    GTCR, Carlyle to buy contract research firm Albany Molecular

    Contract drug manufacturer and research company Albany Molecular Research Inc said on Tuesday it had agreed to be taken private by buyout firms Carlyle Group LP and GTCR LLC for about $922 million in cash. Clinical research organizations can prove to be lucrative investments for private equity firms.

  • The Wall Street Journal3 months ago

    [$$] Carlyle, GTCR to Acquire Contract-Drug Manufacturer

    Contract-drug manufacturer Albany Molecular Research Inc. said Tuesday that it has agreed to be acquired by private-equity firms Carlyle Group LP and GTCR LLC in a deal worth about $933.9 million.